ARMP · Armata Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Innoviva, Inc. Director | ▲ Buy | Open Market | 16,365,969 Shares held | 3/31/2022 | View profile |
| Deborah Birx Director | ▼ Sell | Tax Withholding | 198,417 Shares held | 7/10/2026 | View profile |
| Richard Rychlik Corporate Controller and PFO | ▲ Buy | Grant | 10,000 Shares held | 3/14/2024 | View profile |
| Pierre Kyme Chief Business Officer | ▼ Sell | Tax Withholding | 9,461 Shares held | 3/14/2026 | View profile |
Transaction History
| Deborah Birx | ▼ Sell | Tax Withholding | 14,041 | $60K | 7/10/2026 |
| Pierre Kyme | ▼ Sell | Tax Withholding | 1,030 | $11K | 3/14/2026 |
| Deborah Birx | ▼ Sell | Tax Withholding | 4,919 | $52K | 3/14/2026 |
| Deborah Birx | ▼ Sell | Tax Withholding | 13,637 | $31K | 7/10/2025 |
| Deborah Birx | ▼ Sell | Tax Withholding | 6,061 | $12K | 3/14/2025 |
| Pierre Kyme | ▼ Sell | Tax Withholding | 1,027 | $2K | 3/14/2025 |
| Deborah Birx | ▼ Sell | Tax Withholding | 22,925 | $61K | 7/10/2024 |
| Richard Rychlik | ▲ Buy | Grant | 10,000 | $0 | 3/14/2024 |
| Deborah Birx | ▲ Buy | Grant | 60,000 | $0 | 3/14/2024 |
| Deborah Birx | ▲ Buy | Grant | 200,000 | $0 | 12/21/2023 |
| Innoviva, Inc. | ▲ Buy | Open Market | 5,385,208 | $26.9M | 3/31/2022 |
| Innoviva, Inc. | ▲ Buy | Open Market | 3,614,792 | $18.1M | 2/9/2022 |
| Innoviva, Inc. | ▲ Buy | Open Market | 1,212,122 | $4.0M | 10/29/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial. Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.